# A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers

> **NCT03978403** · PHASE1 · COMPLETED · sponsor: **Zosano Pharma Corporation** · enrollment: 24 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches)
- **DRUG:** M207 3.8 mg "MACAP" (two 1.9 mg patches made on a "MACAP" coater, foil cups)
- **DRUG:** M207 3.8 mg "MiniMac" (two 1.9 mg patches made on a "MiniMac" coater, foil cups
- **DRUG:** Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose

## Key facts

- **NCT ID:** NCT03978403
- **Lead sponsor:** Zosano Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-29
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-06-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03978403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03978403, "A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03978403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*